Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging

This study is ongoing, but not recruiting participants.

Study NCT00592982. Last updated on December 27, 2007. Information provided by University of Arkansas

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging

Official Title ^†

Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging

Brief Summary

Bisphosphonate-associated osteonecrosis of the jaw(ONJ)is detectable by positron emission tomography(PET).
Bisphosphonate-associated ONJ can be diagnosed and characteristically differentiated from other bony pathologies of the jaw(osteomyelitis, osteolytic lesions, and osteoradionecrosis)by PET imaging.

Detailed Description

Is to review medical records of approximately 1000 patients with bisphosphonate-associated ONJ who have had PET imaging at the time of diagnosis. Also to review mediacl records of patients who have been diagnosed with jaw osteomyelitis, osteoradionecrosis, and cancerous lytic lesions who recieved PET imaging at the time of diagnosis.

If sufficient information regarding presentation and treatment cannot be obtained form the medical record, approximately 300 patients will contacted by mail (and phone if necessary) by the PI or sub-investigators to question them reguarding the onset of symptoms, treatment interventions, and outcomes.

Study Phase

Study Type ^†

Observational

Study Design ^†

Cohort, Prospective

Primary Outcome Measure ^†

Secondary Outcome Measure ^†

Condition ^†

Bisphosphonate-Asscoiated ONJ
Osteomyelitis of the Jaw
Osteolytic Lesions of the Jaw
Osteoradionecrosis of the Jaw

Intervention ^†

MEDLINE PMIDs

Links

Recruitment Information Fields

Recruitment Status ^†

Active, not recruiting

Enrollment ^†

1000

Start Date ^†

October 2006

Completion Date

October 2009

Eligibility Criteria ^†

Inclusion Criteria:

Diagnosis of bisphosphonate-associated ONJ, osteomyelitis, osteoradionecrosis,and osteolytic lesions who recieveed PET imaging at presentation

Exclusion Criteria:

Anyone who has not been diagnosed with bisphosphonate-associated ONJ, osteomyelitis, osteoradionecrosis,or osteolytic lesions who recieved PET imaging at presentation

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Administrative Information Fields

NCT ID ^†

NCT00592982

Organization ID

73319

Secondary IDs ^††

Study Sponsor ^†

University of Arkansas

Collaborators ^††

Investigators ^†

Principal Investigator:

Brendan Stack, MD

University of Arkansas

Information Provided By

University of Arkansas

Verification Date

December 2007

First Received Date ^†

December 27, 2007

Last Updated Date

December 27, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.